-
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 TrialDaiichi Sankyo2023-11-09 20:56:34ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in
-
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 TrialDaiichi Sankyo2023-11-09 20:56:43ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer
-
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 TrialDaiichi Sankyo2023-11-09 20:56:52ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric
-
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric CancerDaiichi Sankyo2023-11-09 20:57:08ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
-
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research InstituteDaiichi Sankyo2020-07-24 10:37:21Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research
-
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2020-08-03 09:22:50ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung
-
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual MeetingDaiichi Sankyo2020-07-24 10:39:26Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
-
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-10 06:54:49ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
-
New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI® approved in EuropeDaiichi Sankyo2020-08-03 09:23:48New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI®
-
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary EndpointDaiichi Sankyo2020-01-27 09:31:00Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
